Search research articles
Contact Us
Filters
Showing results (421-430 of 491) with videos related to
Page
of 50
Sort By:
Oncotarget
|
October 27, 2015
Cytoskeletal protein Flightless I inhibits apoptosis, enhances tumor cell invasion and promotes cutaneous squamous cell carcinoma progression
Zlatko Kopecki, Gink N Yang, Jessica E Jackson, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 12, 2021
Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study
J I Silverberg, A Pinter, A Alavi, et al.
The Journal of Dermatological Treatment
|
July 11, 2020
International collaboration
Mitchel P Goldman, Dedee F Murrell, Nawaf Al-Mutairi, et al.
Orphanet Journal of Rare Diseases
|
July 15, 2022
A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex
Jodi Y So, Shivali Fulchand, Christine Y Wong, et al.
Muscle & Nerve
|
June 16, 2011
Epidermolysis bullosa with late-onset muscular dystrophy and plectin deficiency
Eppie M Yiu, Alfred Klausegger, Leigh B Waddell, et al.
The British Journal of Dermatology
|
June 28, 2025
Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up)
Melinda Gooderham, Tiago Torres, Shinichi Imafuku, et al.
The British Journal of Dermatology
|
June 14, 2005
Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial
A B Gottlieb, C E M Griffiths, V C Ho, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 10, 2022
Phase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgaris
D F Murrell, A Patsatsi, P Stavropoulos, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
July 21, 2019
Inter-rater reliability of the BIOCHIP indirect immunofluorescence dermatology mosaic in bullous pemphigoid and pemphigus patients
A Yang, R R Xuan, W Melbourne, et al.
Genome Integrity
|
August 4, 2010
Low levels of ATM in breast cancer patients with clinical radiosensitivity
Zhiming Fang, Sergei Kozlov, Michael J McKay, et al.
Page
of 50
Search research articles
Search
Showing results (421-430 of 491) with videos related to
Sort By:
Page
of 50
Oncotarget
|
October 27, 2015
Cytoskeletal protein Flightless I inhibits apoptosis, enhances tumor cell invasion and promotes cutaneous squamous cell carcinoma progression
Zlatko Kopecki, Gink N Yang, Jessica E Jackson, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 12, 2021
Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study
J I Silverberg, A Pinter, A Alavi, et al.
The Journal of Dermatological Treatment
|
July 11, 2020
International collaboration
Mitchel P Goldman, Dedee F Murrell, Nawaf Al-Mutairi, et al.
Orphanet Journal of Rare Diseases
|
July 15, 2022
A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex
Jodi Y So, Shivali Fulchand, Christine Y Wong, et al.
Muscle & Nerve
|
June 16, 2011
Epidermolysis bullosa with late-onset muscular dystrophy and plectin deficiency
Eppie M Yiu, Alfred Klausegger, Leigh B Waddell, et al.
The British Journal of Dermatology
|
June 28, 2025
Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up)
Melinda Gooderham, Tiago Torres, Shinichi Imafuku, et al.
The British Journal of Dermatology
|
June 14, 2005
Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial
A B Gottlieb, C E M Griffiths, V C Ho, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 10, 2022
Phase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgaris
D F Murrell, A Patsatsi, P Stavropoulos, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
July 21, 2019
Inter-rater reliability of the BIOCHIP indirect immunofluorescence dermatology mosaic in bullous pemphigoid and pemphigus patients
A Yang, R R Xuan, W Melbourne, et al.
Genome Integrity
|
August 4, 2010
Low levels of ATM in breast cancer patients with clinical radiosensitivity
Zhiming Fang, Sergei Kozlov, Michael J McKay, et al.
Page
of 50